Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Clin Pharmacol Ther ; 98(1): 87-95, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25732044

ABSTRACT

This prospective trial investigated the population pharmacokinetics of piperaquine given with dihydroartemisinin to treat uncomplicated malaria in 107 Ugandan children 6 months to 2 years old, an age group previously unstudied. Current weight-based dosing does not adequately address physiological changes in early childhood. Patients were administered standard 3-day oral doses and provided 1,282 capillary plasma concentrations from 218 malaria episodes. Less than 30% of treatments achieved 57 ng/mL on day 7. A three-compartment model with first-order absorption described the data well. Age had a statistically significant effect (P < 0.005) on clearance/bioavailability in a model that accounts for allometric scaling. Simulations demonstrated that higher doses in all children, but especially in those with lower weight for age, are required for adequate piperaquine exposure, although safety and tolerance will need to be established. These findings support other evidence that both weight- and age-specific guidelines for piperaquine dosing in children are urgently needed.


Subject(s)
Antimalarials/pharmacokinetics , Artemisinins/therapeutic use , Malaria/drug therapy , Quinolines/pharmacokinetics , Antimalarials/blood , Antimalarials/therapeutic use , Child, Preschool , Drug Therapy, Combination , Humans , Infant , Prospective Studies , Quinolines/blood , Quinolines/therapeutic use , Uganda
2.
Article in English | MEDLINE | ID: mdl-24226803

ABSTRACT

Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda after a standard fixed oral artemether-lumefantrine treatment. Dense venous (n = 26) and sparse capillary (n = 90) lumefantrine samples were drawn from pregnant patients. A total of 17 nonpregnant women contributed with dense venous lumefantrine samples. Lumefantrine pharmacokinetics was best described by a flexible absorption model with multiphasic disposition. Pregnancy and body temperature had a significant impact on the pharmacokinetic properties of lumefantrine. Simulations from the final model indicated 27% lower day 7 concentrations in pregnant women compared with nonpregnant women and a decreased median time of 0.92 and 0.42 days above previously defined critical concentration cutoff values (280 and 175 ng/ml, respectively). The standard artemether-lumefantrine dose regimen in P. falciparum malaria may need reevaluation in nonimmune pregnant women.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e83; doi:10.1038/psp.2013.59; advance online publication 13 November 2013.

3.
Clin Pharmacol Ther ; 93(5): 443-50, 2013 May.
Article in English | MEDLINE | ID: mdl-23511715

ABSTRACT

Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinetics data on intramuscular ARS are limited with respect to the main treatment group that carries the highest mortality, namely, critically ill children with severe malaria. A population pharmacokinetic study of ARS and dihydroartemisinin (DHA) was conducted from sparse sampling in 70 Tanzanian children of ages 6 months to 11 years. All the children had been admitted with severe falciparum malaria and were treated with intramuscular ARS (2.4 mg/kg at 0, 12, and 24 h). Venous plasma concentration-time profiles were characterized using nonlinear mixed-effects modeling (NONMEM). A one-compartment disposition model accurately described first-dose population pharmacokinetics of ARS and DHA. Body weight significantly affected clearance and apparent volume of distribution (P < 0.001), resulting in lower ARS and DHA exposure levels in smaller children. An adapted dosing regimen including a practical dosing table per weight band is proposed for young children based on the pharmacokinetic model.


Subject(s)
Antimalarials/pharmacokinetics , Artemisinins/pharmacokinetics , Malaria, Falciparum/drug therapy , Models, Biological , Antimalarials/administration & dosage , Antimalarials/therapeutic use , Artemisinins/administration & dosage , Artemisinins/therapeutic use , Artesunate , Body Weight , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Administration Schedule , Humans , Infant , Injections, Intramuscular , Nonlinear Dynamics , Severity of Illness Index , Tanzania , Time Factors , Tissue Distribution
4.
J Antimicrob Chemother ; 68(3): 697-707, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23143901

ABSTRACT

OBJECTIVES: Long-term chemoprophylaxis using neuraminidase inhibitors may be needed during influenza epidemics but safety data are limited to several weeks. We sought to assess the tolerability of oseltamivir and zanamivir as primary prophylaxis over 16 weeks. METHODS: We conducted a parallel group, double blind, 2 (active drug) :1 (placebo) randomized trial of oral oseltamivir/placebo or inhaled zanamivir/placebo over 16 weeks in healthy, Thai hospital professionals at two Bangkok hospitals. The primary endpoint was study withdrawal due to drug-related (possibly, probably, definitely) serious or adverse events (AEs) graded ≥ 2. RESULTS: Recruited subjects numbered 129 oseltamivir/65 placebo and 131 zanamivir/65 placebo. A total of 102 grade ≥ 2 AEs were reported or detected in 69 subjects: 23/129 (17.8%) versus 15/65 (23.1%) (P=0.26), and 23/131 (17.6%) versus 8/65 (12.3%) (P=0.28). Intercurrent infections/fevers [26/102 (25.5%)], abnormal biochemistry [25/102 (24.5%)] and gastrointestinal symptoms [18/102 (17.6%)] were the most frequently reported AEs. There were no drug-related study withdrawals. Eight serious AEs were all due to intercurrent illnesses. Laboratory, lung function and ECG parameters were similar between drugs and placebos. CONCLUSIONS: Oseltamivir and zanamivir were well tolerated in healthy hospital professionals. Both drugs can be recommended for primary influenza prophylaxis for up to 16 weeks.


Subject(s)
Antiviral Agents/adverse effects , Chemoprevention/adverse effects , Health Personnel , Influenza, Human/prevention & control , Oseltamivir/adverse effects , Zanamivir/adverse effects , Administration, Inhalation , Adult , Antiviral Agents/administration & dosage , Chemoprevention/methods , Double-Blind Method , Drug-Related Side Effects and Adverse Reactions/epidemiology , Female , Humans , Male , Middle Aged , Oseltamivir/administration & dosage , Placebos/administration & dosage , Thailand , Young Adult , Zanamivir/administration & dosage
5.
Clin Pharmacol Ther ; 91(3): 497-505, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22258469

ABSTRACT

Dihydroartemisinin-piperaquine is being increasingly used as a first-line artemisinin combination treatment for malaria. The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso. They received a standard body weight-based oral 3-day fixed-dose dihydroartemisinin-piperaquine regimen. Capillary plasma concentration-time profiles were characterized using nonlinear mixed-effects modeling. The population pharmacokinetics of piperaquine were described accurately by a two-transit-compartment absorption model and a three-compartment distribution model. Body weight was a significant covariate affecting clearance and volume parameters. The individually predicted day 7 capillary plasma concentration of piperaquine was an important predictor (P < 0.0001) of recurrent malaria infection after treatment. Young children (2-5 years of age) received a significantly higher body weight-normalized dose than older children (P = 0.025) but had significantly lower day 7 piperaquine concentrations (P = 0.024) and total piperaquine exposures (P = 0.021), suggesting that an increased dose regimen for young children should be evaluated.


Subject(s)
Malaria, Falciparum/drug therapy , Malaria, Falciparum/metabolism , Quinolines/administration & dosage , Quinolines/pharmacokinetics , Artemisinins/administration & dosage , Body Weight , Burkina Faso , Child , Child, Preschool , Drug Therapy, Combination/methods , Female , Humans , Male , Quinolines/adverse effects , Quinolines/blood
6.
J Pharm Biomed Anal ; 49(3): 768-73, 2009 Apr 05.
Article in English | MEDLINE | ID: mdl-19162422

ABSTRACT

A liquid chromatographic tandem mass spectroscopy method for the quantification of artemisinin in human heparinised plasma has been developed and validated. The method uses Oasis HLB mu-elution solid phase extraction 96-well plates to facilitate a high throughput of 192 samples a day. Artesunate (internal standard) in a plasma-water solution was added to plasma (50 microL) before solid phase extraction. Artemisinin and its internal standard artesunate were analysed by liquid chromatography and MS/MS detection on a Hypersil Gold C18 (100 mm x 2.1 mm, 5 microm) column using a mobile phase containing acetonitrile-ammonium acetate 10mM pH 3.5 (50:50, v/v) at a flow rate of 0.5 mL/min. The method has been validated according to published FDA guidelines and showed excellent performance. The within-day, between-day and total precisions expressed as R.S.D., were lower than 8% at all tested quality control levels including the upper and lower limit of quantification. The limit of detection was 0.257 ng/mL for artemisinin and the calibration range was 1.03-762 ng/mL using 50 microL plasma. The method was free from matrix effects as demonstrated both graphically and quantitatively.


Subject(s)
Antimalarials/blood , Artemisinins/blood , Analysis of Variance , Antimalarials/pharmacokinetics , Artemisinins/pharmacokinetics , Artesunate , Biological Availability , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Humans , Indicators and Reagents , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry
7.
Antimicrob Agents Chemother ; 53(3): 945-52, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19104028

ABSTRACT

The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four increasing dose levels in groups of eight healthy adult Thai volunteers (125 individual series) were evaluated. Doses of up to 675 mg were well-tolerated. The pharmacokinetics were dose linear. Oseltamivir phosphate (OS) was rapidly and completely absorbed and converted (median conversion level, 93%) to the active carboxylate metabolite. Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC). One subject repeatedly showed markedly reduced OS-to-OC conversion, indicating constitutionally impaired carboxylesterase activity. The coadministration of probenecid resulted in a mean contraction in the apparent volume of distribution of OC of 40% (95% CI, 37 to 44%) and a reduction in the renal elimination of OC of 61% (95% CI, 58 to 62%), thereby increasing the median area under the concentration-time curve (AUC) for OC by 154% (range, 71 to 278%). The AUC increase for OC in saliva was approximately three times less than the AUC increase for OC in plasma. A loading dose 1.25 times the maintenance dose should be given for severe influenza pneumonia. Probenecid coadministration may allow considerable dose saving for oseltamivir, but more information on OC penetration into respiratory secretions is needed to devise appropriate dose regimens.


Subject(s)
Antiviral Agents/pharmacokinetics , Oseltamivir/pharmacokinetics , Administration, Oral , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Area Under Curve , Asian People/genetics , Biological Availability , Dose-Response Relationship, Drug , Drug Interactions , Female , Half-Life , Humans , Influenza A Virus, H5N1 Subtype/metabolism , Influenza, Human/drug therapy , Male , Metabolic Clearance Rate , Models, Biological , Nausea/chemically induced , Oseltamivir/administration & dosage , Oseltamivir/adverse effects , Oseltamivir/blood , Probenecid/administration & dosage , Probenecid/pharmacokinetics , Saliva , Thailand , Urinalysis , Vomiting/chemically induced
8.
Article in English | MEDLINE | ID: mdl-18980865

ABSTRACT

A bioanalytical method for the analysis of artesunate (ARS) and its metabolite dihydroartemisinin (DHA) in human plasma using protein precipitation and liquid chromatography coupled to positive tandem mass spectroscopy was developed. The method was validated according to published US FDA-guidelines and showed excellent performance. However, when it was applied to clinical pharmacokinetic studies in malaria, variable degradation of the artemisinins introduced an unacceptable large source of error, rendering the assay useless. Haemolytic products related to sample collection and malaria infection degraded the compounds. Addition of organic solvents during sample processing and even low volume addition of the internal standard in an organic solvent caused degradation. A solid phase extraction method avoiding organic solvents eliminated problems arising from haemolysis induced degradation. Plasma esterases mediated only approximately 20% of ex vivo hydrolysis of ARS into DHA. There are multiple sources of major preventable error in measuring ARS and DHA in plasma samples from clinical trials. These various pitfalls have undoubtedly contributed to the large inter-subject variation in plasma concentration profiles and derived pharmacokinetic parameters for these important antimalarial drugs.


Subject(s)
Antimalarials/blood , Artemisinins/blood , Anticoagulants/pharmacology , Artemisinins/pharmacokinetics , Artemisinins/therapeutic use , Female , Hemolysis , Humans , Malaria, Falciparum/drug therapy , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Solid Phase Extraction/methods , Tandem Mass Spectrometry/methods , Temperature
9.
J Chromatogr A ; 1215(1-2): 145-51, 2008 Dec 26.
Article in English | MEDLINE | ID: mdl-19026421

ABSTRACT

An assay for the analysis for the quantification of the anti-influenza drug peramivir in human plasma using high-throughput zwitterionic (ZIC) hydrophilic interaction liquid chromatography (HILIC) solid-phase extraction (SPE) in a 96-wellplate format and liquid chromatography coupled to positive tandem mass spectroscopy has been developed and validated. The ZIC-HILIC SPE efficiently removed sources of interference present in the supernatant after protein precipitation of plasma proteins. The main advantage of the ZIC-HILIC SPE sample preparation step was that it allowed load and elution conditions to be optimised to extract only peramivir and minimize co-extraction of lipophilic phospholipids. The method was validated according to published US Food and Drugs Administration guidelines and showed excellent performance. The assay was validated over two calibration ranges (0.952-500 and 50-50,000 ng/mL) to support analysis of peramivir after intra-venous administration. The lower limit of quantification for peramivir in plasma was 1 ng/mL and the upper limit of quantification was 50,000 ng/mL. The within-day and between-day precisions expressed as RSD, were lower than 8% at all tested quality control concentrations and below 11% at the lower limit of quantification. Validation of over-curve samples ensured that it would be possible with dilution if samples went outside the calibration range.


Subject(s)
Antiviral Agents/blood , Chromatography, Liquid/methods , Cyclopentanes/blood , Guanidines/blood , Tandem Mass Spectrometry/methods , Acids, Carbocyclic , Humans , Reference Standards , Reproducibility of Results
10.
Article in English | MEDLINE | ID: mdl-18990614

ABSTRACT

A bioanalytical method for the analysis of artesunate and its metabolite dihydroartemisinin in human plasma using high throughput solid-phase extraction in the 96-wellplate format and liquid chromatography coupled to positive tandem mass spectroscopy has been developed and validated. The method was validated according to published FDA guidelines and showed excellent performance. The within-day and between-day precisions expressed as RSD, were lower than 7% at all tested concentrations including the lower limit of quantification. Using 50 microl plasma the calibration range was 1.19-728 ng/ml with a limit of detection at 0.5 ng/ml for artesunate and 1.96-2500 ng/ml with a limit of detection at 0.6 ng/ml for dihydroartemisinin. Using 250 microl of plasma sample the lower limit of quantification was decreased to 0.119 ng/ml for artesunate and 0.196 ng/ml dihydroartemisinin. Validation of over-curve samples in plasma ensured that accurate estimation would be possible with dilution if samples went outside the calibration range. The method was free from matrix effects as demonstrated both graphically and quantitatively.


Subject(s)
Artemisinins/blood , Chromatography, Liquid/methods , Tandem Mass Spectrometry/methods , Artesunate , Humans , Reproducibility of Results , Sensitivity and Specificity , Spectrometry, Mass, Electrospray Ionization/methods , Uncertainty
11.
J Chromatogr B Analyt Technol Biomed Life Sci ; 862(1-2): 227-36, 2008 Feb 01.
Article in English | MEDLINE | ID: mdl-18191623

ABSTRACT

A bioanalytical method for the analysis of piperaquine in human plasma using off-line solid-phase extraction and liquid chromatography coupled to positive tandem mass spectroscopy has been developed and validated. It was found that a mobile phase with high pH (i.e. 10) led to better sensitivity than mobile phase combinations with low pH (i.e. 2.5-4.5) despite the use of positive electrospray and a basic analyte. The method was validated according to published FDA guidelines and showed excellent performance. The within-day and between-day precisions expressed as R.S.D., were lower than 7% at all tested concentrations (4.5, 20, 400 and 500ng/mL) and below 10% at the lower limit of quantification (LLOQ) (1.5ng/mL). The calibration range was 1.5-500ng/mL with a limit of detection (LOD) at 0.38ng/mL. Validation of over-curve samples ensured that it would be possible with dilution if samples went outside the calibration range. Matrix effects were thoroughly evaluated both graphically and quantitatively. Matrix effects originating from the sample clean-up (i.e. solid-phase extraction) procedure rather than the plasma background were responsible for the ion suppression seen in this study. Salts remaining from the buffers used in the solid-phase extraction suppressed the signals for both piperaquine and its deuterated internal standard. This had no effect on the quantification of piperaquine. Triethylamine residues remaining after evaporation of the solid-phase extraction eluate were found to suppress the signals for piperaquine and its deuterated internal standard differently. It was found that this could lead to an underestimation of the true concentration with 50% despite the use of a deuterated internal standard.


Subject(s)
Antimalarials/blood , Chromatography, Liquid/methods , Quinolines/blood , Tandem Mass Spectrometry/methods , Calibration , Isotopes , Reference Standards , Sensitivity and Specificity
12.
Antimicrob Agents Chemother ; 52(3): 1052-61, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18180343

ABSTRACT

The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens. Children had a lower body weight-normalized oral clearance than adults, resulting in longer terminal elimination half-lives and higher total exposure to piperaquine (area under the concentration-time curve from 0 to 63 days [AUC day 0-63]). However, children had lower plasma concentrations in the therapeutically relevant posttreatment prophylactic period (AUC day 3-20) because of smaller body weight-normalized central volumes of distribution and shorter distribution half-lives. Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults.


Subject(s)
Antimalarials/pharmacokinetics , Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Quinolines/pharmacokinetics , Quinolines/therapeutic use , Adolescent , Adult , Animals , Antimalarials/administration & dosage , Area Under Curve , Artemisinins/administration & dosage , Child , Child, Preschool , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Malaria, Falciparum/parasitology , Male , Middle Aged , Quinolines/administration & dosage , Thailand , Treatment Outcome
13.
J Pharm Sci ; 97(8): 3400-10, 2008 Aug.
Article in English | MEDLINE | ID: mdl-17969131

ABSTRACT

This study aimed to evaluate the pharmacokinetic properties of piperaquine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration. Male Sprague-Dawley rats were administered piperaquine as an emulsion orally or as a short-term intravenous infusion. Venous blood for pharmacokinetic evaluation was frequently withdrawn up to 90 h after dose. Urine, bile and faeces were collected after an infusion in rats kept in metabolic cages or in anesthetized rats. Pharmacokinetic characterization was done by compartmental modeling and non-compartmental analysis using WinNonlin. Piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after intravenous administration. The pharmacokinetics of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life. Piperaquine displayed a low biliary clearance and less than 1% of the total dose was recovered in urine. The absolute oral bioavailability was approximately 50%. The main metabolite after intravenous administration of piperaquine was a carboxylic acid product identical to that reported in humans. The similarity with results in humans indicates the rat to be a suitable species for nonclinical in vivo piperaquine studies.


Subject(s)
Antimalarials/pharmacokinetics , Quinolines/pharmacokinetics , Administration, Oral , Animals , Antimalarials/administration & dosage , Biological Availability , Half-Life , Infusions, Intravenous , Male , Quinolines/administration & dosage , Rats , Rats, Sprague-Dawley
14.
Article in English | MEDLINE | ID: mdl-17913596

ABSTRACT

A bioanalytical method for the analysis of oseltamivir (OP) and its metabolite oseltamivir carboxylate (OC) in human plasma, saliva and urine using off-line solid-phase extraction and liquid chromatography coupled to positive tandem mass spectroscopy has been developed and validated. OP and OC were analysed on a ZIC-HILIC column (50 mm x 2.1 mm) using a mobile phase gradient containing acetonitrile-ammonium acetate buffer (pH 3.5; 10mM) at a flow rate of 500 microL/min. The method was validated according to published FDA guidelines and showed excellent performance. The lower limit of quantification for OP was determined to be 1, 1 and 5 ng/mL for plasma, saliva and urine, respectively and for OC was 10, 10 and 30 ng/mL for plasma, saliva and urine, respectively. The upper limit of quantification for OP was determined to be 600, 300 and 1500 ng/mL for plasma, saliva and urine, respectively and for OC was 10,000, 10,000 and 30,000 ng/mL for plasma, saliva and urine, respectively. The within-day and between-day precisions expressed as R.S.D., were lower than 5% at all tested concentrations for all matrices and below 12% at the lower limit of quantification. Validation of over-curve samples ensured that it would be possible with dilution if samples went outside the calibration range. Matrix effects were thoroughly evaluated both graphically and quantitatively. No matrix effects were detected for OP or OC in plasma or saliva. Residues from the urine matrix (most likely salts) caused some ion suppression for both OP and its deuterated internal standard but had no effect on OC or its deuterated internal standard. The suppression did not affect the quantification of OP.


Subject(s)
Antiviral Agents/analysis , Chromatography, Liquid/methods , Oseltamivir/analysis , Tandem Mass Spectrometry/methods , Antiviral Agents/blood , Antiviral Agents/urine , Drug Stability , Humans , Oseltamivir/blood , Oseltamivir/urine , Reference Standards , Reproducibility of Results , Saliva/chemistry
15.
Antimicrob Agents Chemother ; 51(11): 4090-7, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17846129

ABSTRACT

Dihydroartemisinin-piperaquine (DHP) is an important new treatment for drug-resistant malaria, although pharmacokinetic studies on the combination are limited. In Papua, Indonesia, we assessed determinants of the therapeutic efficacy of DHP for uncomplicated malaria. Plasma piperaquine concentrations were measured on day 7 and day 28, and the cumulative risk of parasitological failure at day 42 was calculated using survival analysis. Of the 598 patients in the evaluable population 342 had infections with Plasmodium falciparum, 83 with Plasmodium vivax, and 173 with a mixture of both species. The unadjusted cumulative risks of recurrence were 7.0% (95% confidence interval [CI]: 4.6 to 9.4%) for P. falciparum and 8.9% (95% CI: 6.0 to 12%) for P. vivax. After correcting for reinfections the risk of recrudescence with P. falciparum was 1.1% (95% CI: 0.1 to 2.1%). The major determinant of parasitological failure was the plasma piperaquine concentration. A concentration below 30 ng/ml on day 7 was observed in 38% (21/56) of children less than 15 years old and 22% (31/140) of adults (P = 0.04), even though the overall dose (mg per kg of body weight) in children was 9% higher than that in adults (P < 0.001). Patients with piperaquine levels below 30 ng/ml were more likely to have a recurrence with P. falciparum (hazard ratio [HR] = 6.6 [95% CI: 1.9 to 23]; P = 0.003) or P. vivax (HR = 9.0 [95% CI: 2.3 to 35]; P = 0.001). The plasma concentration of piperaquine on day 7 was the major determinant of the therapeutic response to DHP. Lower plasma piperaquine concentrations and higher failure rates in children suggest that dose revision may be warranted in this age group.


Subject(s)
Artemisinins/therapeutic use , Malaria/drug therapy , Quinolines/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Antimalarials/administration & dosage , Antimalarials/pharmacokinetics , Antimalarials/therapeutic use , Artemisinins/blood , Artemisinins/pharmacokinetics , Child , Child, Preschool , Drug Administration Schedule , Female , Humans , Indonesia , Infant , Male , Middle Aged , Prospective Studies , Quinolines/blood , Quinolines/pharmacokinetics , Sesquiterpenes/blood , Sesquiterpenes/pharmacokinetics , Survival Analysis , Treatment Outcome
16.
J Pharm Biomed Anal ; 45(2): 282-7, 2007 Oct 18.
Article in English | MEDLINE | ID: mdl-17719735

ABSTRACT

A bioanalytical method for the determination of lumefantrine in 100 microl blood applied onto sampling paper, by solid-phase extraction and liquid chromatography, has been developed and validated. Whatman 31 ET Chr sampling paper was pre-treated with 0.75 M tartaric acid before sampling capillary blood to enable a high recovery of lumefantrine. Lumefantrine was extracted from the sampling paper, then further purified using solid-phase extraction and finally quantified with HPLC. The between-day variation was below 10% over the range 0.4-25 microM. The lower limit of quantification was 0.25 microM in 100 microl capillary blood. No decrease in lumefantrine concentration in dried blood spot is seen after 4 months storage at 22 degrees C. The method was also evaluated in field samples from patients in Tanzania after treatment with lumefantrine/artemether. Lumefantrine could be estimated accurately enough to assess bioavailability and treatment compliance on day 7 (i.e. 4 days after the last dose) after a standard regimen with the lumefantrine/artemether combination.


Subject(s)
Antimalarials/blood , Antimalarials/isolation & purification , Chromatography, Liquid/methods , Ethanolamines/blood , Ethanolamines/isolation & purification , Fluorenes/blood , Fluorenes/isolation & purification , Humans , Lumefantrine , Paper , Reproducibility of Results , Sensitivity and Specificity , Solid Phase Extraction
17.
J Pharm Biomed Anal ; 45(1): 149-153, 2007 Sep 21.
Article in English | MEDLINE | ID: mdl-17553648

ABSTRACT

A simple and rapid liquid chromatographic-mass spectrometric assay for the evaluation of artesunate in vials for injection has been developed and validated. The content of each vial was dissolved in 3.0 mL of methanol using a SGE analytical syringe (1.0 mL). Each sample was diluted to a theoretical concentration of 1000 ng/mL and analysed in triplicate. Three replicates of calibration standards at concentrations 500, 1000 and 1500 ng/mL were used to construct a calibration curve. Artesunate was analysed by liquid chromatography with atmospheric pressure chemical ionisation (APCI) mass spectrometric (MS) detection on a Hypersil Gold column (100 mm x 4.6 mm) using a mobile phase containing methanol-ammonium acetate 10 mM pH 5.3 (70:30, v/v) at a flow rate of 1 mL/min. The assay was implemented for the analysis of artesunate for injection purchased from Guilin Pharmaceutical Company in China.


Subject(s)
Antimalarials/analysis , Artemisinins/analysis , Chemistry, Pharmaceutical/methods , Pharmaceutical Preparations/analysis , Sesquiterpenes/analysis , Artesunate , Calibration , Chromatography, Liquid , Mass Spectrometry , Pharmaceutical Preparations/standards , Quality Control , Reference Standards , Reproducibility of Results
18.
J Chromatogr A ; 1135(2): 166-9, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17046006

ABSTRACT

A significant contaminant of the antimalarial drug piperaquine (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]propane) has been identified using liquid chromatography-mass spectrometry (LC-MS) and 2D NMR spectroscopy (1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC). The impurity was identified as the positional isomer 1-[(5-chloroquinolin-4)-piperazinyl]-3-[(7-chloroquinolin-4)-piperazinyl]propane. The impurity is formed because of contamination of batches of 4,7-dichloroquinoline (a precursor in the synthesis of piperaquine) with 4,5-dichloroquinoline. The amount of impurity (peak area impurity/peak area piperaquine using LC-UV at 347 nm) in old batches of piperaquine and in Artekin (the combination of dihydroartemisinin-piperaquine) ranged from 1.5 to 5%.


Subject(s)
Antimalarials/chemistry , Quinolines/chemistry , Chromatography, Liquid , Isomerism , Magnetic Resonance Spectroscopy , Spectrophotometry, Ultraviolet
19.
Drug Metab Dispos ; 34(12): 2011-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16956956

ABSTRACT

Five metabolites of the antimalarial piperaquine (PQ) (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane) have been identified and their molecular structures characterized. After a p.o. dose of dihydroartemisinin-piperaquine, urine collected over 16 h from two healthy subjects was analyzed using liquid chromatography (LC)/UV, LC/tandem mass spectrometry (MS/MS), Fourier transform ion cyclotron resonance (FTICR)/MS, and H NMR. Five different peaks were recognized as possible metabolites [M1, 320 m/z; M2, M3, and M4, 551 m/z (PQ + 16 m/z); and M5, 567 m/z (PQ + 32 m/z)] using LC/MS/MS with gradient elution. The proposed carboxylic M1 has a theoretical monoisotopic molecular mass of 320.1166 m/z, which is in accordance with the FTICR/MS (320.1168 m/z) findings. The LC/MS/MS results also showed a 551 m/z metabolite (M2) with a distinct difference both in polarity and fragmentation pattern compared with PQ, 7-hydroxypiperaquine, and the other 551 m/z metabolites. We suggest that this is caused by N-oxidation of PQ. The results showed two metabolites (M3 and M4) with a molecular ion at 551 m/z and similar fragmentation pattern as both PQ and 7-hydroxypiperaquine; therefore, they are likely to be hydroxylated PQ metabolites. The molecular structures of M1 and M2 were also confirmed using H NMR. Urinary excretion rate in one subject suggested a terminal elimination half-life of about 53 days for M1. Assuming formation rate-limiting kinetics, this would support recent findings that the terminal elimination half-life of PQ has been underestimated previously.


Subject(s)
Antimalarials/urine , Quinolines/urine , Antimalarials/blood , Antimalarials/pharmacokinetics , Artemisinins/blood , Artemisinins/pharmacokinetics , Artemisinins/urine , Chromatography, Liquid , Drug Combinations , Humans , Magnetic Resonance Spectroscopy , Male , Quinolines/blood , Quinolines/pharmacokinetics , Sesquiterpenes/blood , Sesquiterpenes/pharmacokinetics , Sesquiterpenes/urine , Tandem Mass Spectrometry
20.
Trop Med Int Health ; 11(8): 1157-65, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16903879

ABSTRACT

OBJECTIVE: To determine the efficacy and safety of oral dihydroartemisinin-piperaquine (DP, Artekin) in the treatment of uncomplicated Plasmodium falciparum malaria in southern Laos. METHODS: An open, randomized clinical trial of oral artesunate-mefloquine (AM) vs. DP in 220 patients with acute uncomplicated falciparum malaria in Savannakhet Province, Laos. RESULTS: The 42-day cure rates (95% CI), as determined by survival analysis and adjusted for reinfection, were excellent and similar for the two groups [99 (94-100)% and 100 (100-100)% for AM and DP, respectively]. The median (range) fever and parasite clearance times for the AM and DP groups were also similar [20 (4-63) h and 2 (1-4) days vs. 20 (7-57) and 2 (1-4) days, logrank P = 0.4 and 0.17, respectively]. There were more patients with at least one potential side effect following treatment in the AM group when compared with the DP group [64/110 (58%) vs. 48/110 (44%), respectively, P = 0.031]. CONCLUSION: Dihydroartemisinin-piperaquine did not have superior efficacy to AM for the treatment of uncomplicated falciparum malaria in Laos but was associated with fewer adverse effects.


Subject(s)
Antimalarials/administration & dosage , Artemisinins/administration & dosage , Malaria, Falciparum/drug therapy , Mefloquine/administration & dosage , Quinolines/administration & dosage , Sesquiterpenes/administration & dosage , Administration, Oral , Adolescent , Adult , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Child , Drug Therapy, Combination , Female , Humans , Laos/epidemiology , Malaria, Falciparum/epidemiology , Male , Mefloquine/adverse effects , Parasitemia/drug therapy , Parasitemia/epidemiology , Quinolines/adverse effects , Quinolines/blood , Recurrence , Sesquiterpenes/adverse effects , Treatment Failure , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...